Cidara Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $0 | $302 | $8,463 | $17,583 |
Gross Profit | 245 | 6,900 | 16,447 | |
EBITDA | -17,333 | -11,064 | -10,270 | |
EBIT | -17,394 | -11,121 | -10,326 | |
Net Income | -15,535 | -89,410 | -10,326 | -5,611 |
Net Change In Cash | 0 | 302 | 8,463 | 17,583 |
Free Cash Flow | -36,801 | -103,780 | -6,667 | -12,900 |
Cash | 127,386 | 164,369 | 29,018 | 35,778 |
Basic Shares | 6,530 | 4,563 | 4,537 | 4,530 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $63,905 | $64,288 | $49,572 | $12,067 |
Gross Profit | 62,382 | 64,288 | 49,572 | -55,950 |
EBITDA | -24,365 | -28,493 | -43,485 | -71,563 |
EBIT | -24,483 | -29,718 | -42,255 | -71,849 |
Net Income | -22,931 | -29,799 | -43,909 | -72,373 |
Net Change In Cash | 63,905 | 64,288 | 49,572 | 12,067 |
Cost of Revenue | -29,542 | -17,319 | ||
Free Cash Flow | -22,937 | -28,591 | -25,273 | -54,597 |
Cash | 35,778 | 32,731 | 62,273 | 35,912 |
Basic Shares | 4,371 | 3,492 | 2,622 | 2,077 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$2.45 |
2024-06-30 | -$19.99 |
2024-03-31 | -$2.28 |
2023-12-31 | -$0.04 |
